UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The history and future of targeting cyclin-dependent kinases in cancer therapy

Nature reviews. Drug discovery, 2015-02, Vol.14 (2), p.130-146

2015

Volltextzugriff (PDF)

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Cell reports (Cambridge), 2016-02, Vol.14 (5), p.979-990

2016

Volltextzugriff (PDF)

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies

Trends in Cancer, 2017-01, Vol.3 (1), p.39-55

2017

Volltextzugriff (PDF)

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Nature communications, 2015-04, Vol.6 (1), p.6744-6744, Article 6744

2015

Volltextzugriff (PDF)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Breast cancer research : BCR, 2014-05, Vol.16 (3), p.207-207, Article 207

2014

Volltextzugriff (PDF)

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Clinical cancer research, 2017-08, Vol.23 (15), p.4429-4440

2017

Volltextzugriff (PDF)

MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies

Cell reports (Cambridge), 2014-12, Vol.9 (6), p.2233-2249

2014

Volltextzugriff (PDF)

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Cancer research (Chicago, Ill.), 2017-05, Vol.77 (9), p.2488-2499

2017

Volltextzugriff (PDF)

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Cancer cell, 2018-11, Vol.34 (5), p.807-822.e7

2018

Volltextzugriff (PDF)

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

Endocrine-related cancer, 2011-06, Vol.18 (3), p.333-345

2011

Volltextzugriff (PDF)

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer

Cell reports (Cambridge), 2016-08, Vol.16 (7), p.2017-2031

2016

Volltextzugriff (PDF)

Targeting the RB-pathway in Cancer Therapy

Clinical cancer research, 2010-02, Vol.16 (4), p.1094-1099

2010

Volltextzugriff (PDF)

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

The Journal of clinical investigation, 2010-12, Vol.120 (12), p.4478-4492

2010

Volltextzugriff (PDF)

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Gastroenterology (New York, N.Y. 1943), 2016-01, Vol.150 (1), p.48-63

2016

Volltextzugriff (PDF)

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

Cell cycle (Georgetown, Tex.), 2012-07, Vol.11 (14), p.2756-2761

2012

Volltextzugriff (PDF)

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Cell reports (Cambridge), 2018-01, Vol.22 (5), p.1185-1199

2018

Volltextzugriff (PDF)

Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics

Cell cycle (Georgetown, Tex.), 2011-04, Vol.10 (8), p.1271-1286

2011

Volltextzugriff (PDF)

Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease

Clinical cancer research, 2016-07, Vol.22 (14), p.3606-3617

2016

Volltextzugriff (PDF)

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy

Trends in Cancer, 2019-05, Vol.5 (5), p.308-324

2019

Volltextzugriff (PDF)

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control

Oncotarget, 2018-07, Vol.9 (57), p.30940-30941

2018

Volltextzugriff (PDF)

The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis

Cancer research (Chicago, Ill.), 2010, Vol.70 (1), p.212-220

2010

Volltextzugriff (PDF)

The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy

Cell cycle (Georgetown, Tex.), 2015-12, Vol.14 (24), p.3812-3819

2015

Volltextzugriff (PDF)

RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response

Cell cycle (Georgetown, Tex.), 2010-10, Vol.9 (20), p.4153-4163

2010

Volltextzugriff (PDF)

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential

Oncotarget, 2016-11, Vol.7 (48), p.78396-78411

2016

Volltextzugriff (PDF)

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

Cell cycle (Georgetown, Tex.), 2012-07, Vol.11 (14), p.2747-2755

2012

Volltextzugriff (PDF)

1 – 25 von 970

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(852)
Mit Volltextzugriff
(857)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(619)
Life Sciences & Biomedicine
(490)
Humans
(301)
Animals
(179)
Female
(172)
Male
(147)
Biological And Medical Sciences
(140)
Physical Sciences
(114)
Oncology
(91)
Middle Aged
(87)
Adult
(85)
Mice
(81)
Cell Biology
(78)
Medical Sciences
(77)
Biochemistry & Molecular Biology
(74)
Fundamental And Applied Biological Sciences. Psychology
(72)
Technology
(69)
Cell Cycle
(63)
Aged
(62)
Retinoblastoma Protein - Metabolism
(62)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The history and future of targeting cyclin-dependent kinases in cancer therapy

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer

Targeting the RB-pathway in Cancer Therapy

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics

Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control

The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis

The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy

RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

Suchergebnisse filtern